Resource Type

Journal Article 200

Year

2023 21

2022 19

2021 23

2020 7

2019 18

2018 14

2017 5

2016 14

2015 11

2014 8

2013 10

2012 14

2011 7

2010 7

2009 10

2008 2

2007 3

2000 2

open ︾

Keywords

cancer 27

lung cancer 16

breast cancer 8

cervical cancer 8

cancer therapy 7

Cancer 5

Colorectal cancer 5

targeted therapy 5

prostate cancer 4

Diagnosis 3

cancer immunotherapy 3

drug resistance 3

immunotherapy 3

Artificial intelligence 2

Breast cancer 2

COVID-19 2

Coronavirus disease 2019 2

DNA methylation 2

Exosomes 2

open ︾

Search scope:

排序： Display mode:

The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China

Yize Xiao, Ying Shao, Xianjun Yu, Guangbiao Zhou

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 388-394 doi: 10.1007/s11684-012-0233-3

Abstract: Unfortunately, the lung cancer morbidity and mortality rates in this region are among China’s highestIn 2004–2005, the crude death rate of lung cancer was 91.3 per 100 000 in the whole Xuanwei CityThe epidemiologic distribution (clustering patterns by population, time, and space) of lung cancer inThe main factor that associates with a high rate of lung cancer incidence was found to be indoor airthe key to diminish lung cancer morbidity and mortality.

Keywords： lung cancer     Xuanwei     smoky coal combustion     polycyclic aromatic hydrocarbons     epidemiology    

HTML PDF Collect

FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 714-728 doi: 10.1007/s11684-022-0959-5

Abstract: Here, we demonstrate the involvement of FRMD6 in lung cancer progression.We find that FRMD6 is overexpressed in lung cancer tissues relative to in normal lung tissues.In addition, the enhanced expression of FRMD6 is associated with poor outcomes in patients with lungcancer cells.Altogether, our results show that FRMD6 contributes to lung cancer progression by activating the mTOR

Keywords： FRMD6     lung cancer     mTOR pathway    

HTML PDF Collect

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 18-42 doi: 10.1007/s11684-022-0976-4

Abstract: With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC), expanding

Keywords： non-small cell lung cancer     driver mutations     treatment strategy     resistant mechanism     immune-checkpoint    

HTML PDF Collect

Pathogenesis sequences in Gejiu miners with lung cancer: an introduction

Li Bian,Yonghua Ruan,Liju Ma,Hairong Hua,Li Zhou,Xiaoyu Tuo,Zheyan Zhou,Ting Li,Shiyue Liu,Kewei Jin

Frontiers of Medicine 2015, Volume 9, Issue 3,   Pages 344-349 doi: 10.1007/s11684-015-0399-6

Abstract:

Tin miners in Gejiu, Yunnan Province, China are at high risk of developing lung cancer with significantpresented pathological characteristics, such as fibroplasia in carcinomas, peri-cancerous tissue in lungOur findings suggested that pulmonary fibrosis may increase the risk and promote the occurrence of lungcancer, which can lead to lung fiber hyperplasia.

Keywords： Yunnan tin mine     miners     lung cancer    

HTML PDF Collect

Curbing the burden of lung cancer

Alexandra Urman,H. Dean Hosgood

Frontiers of Medicine 2016, Volume 10, Issue 2,   Pages 228-232 doi: 10.1007/s11684-016-0447-x

Abstract:

Lung cancer contributes substantially to the global burden of disease and healthcare costs.The International Agency for Research on Cancer has identified several lung carcinogens, which we believeTo curb the societal burden of lung cancer, healthcare resources need to be focused on early detectionFor instance, smoking-attributed lung cancer involves novel genetic markers of risk compared with HAP-attributedlung cancer.

Keywords： lung cancer     screening     risk factors     environmental    

HTML PDF Collect

Orlistat induces ferroptosis-like cell death of lung cancer cells

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 922-932 doi: 10.1007/s11684-020-0804-7

Abstract: synthesis is involved in the progression and treatment resistance of many types of cancers, including lungcancer; however, targeting the lipogenetic pathways for cancer therapy remains an unmet clinical need, and we found that orlistat, as a single agent, inhibited the proliferation and viabilities of lunganticancer activity of orlistat and provided the rationale for repurposing this drug for the treatment of lungcancer and other types of cancer.

Keywords： orlistat     ferroptosis     FAF2     lung cancer    

HTML PDF Collect

Low-dose CT for lung cancer screening: opportunities and challenges

Hongbing Shen

Frontiers of Medicine 2018, Volume 12, Issue 1,   Pages 116-121 doi: 10.1007/s11684-017-0600-1

Abstract:

Lung cancer is among the most frequently diagnosed cancers worldwide and the leading cause of cancerScreening for lung cancer coupled with earlier intervention has long been studied as an approach to mortalitycancer in a randomized controlled trial (RCT), the National Lung Screening Trial, from the United StatesOn the basis of this finding, LDCT has been recommended for lung cancer screening in high-risk populationsComplementary biomarkers and technical improvement are expected in the field of lung cancer screening

Keywords： lung cancer     low-dose computerized tomography     early detection     opportunities     challenges    

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: Lung cancer is one of the most common human cancers and the number one cancer killer in the United StatesIn general, lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), but NSCLC accounts for approximately 90% of lung cancer.tools, which can improve current early detection to reduce mortality from lung cancer, do not exist.These molecular markers in NSCLC demonstrated close associations with the development of lung cancer

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

Four-protein model for predicting prognostic risk of lung cancer

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 618-626 doi: 10.1007/s11684-021-0867-0

Abstract: Patients with lung cancer at the same stage may have markedly different overall outcome and a lack ofspecific biomarker to predict lung cancer outcome.cancer.that the joint detection of HSP90β, CEA, CA125, and CYFRA21-1 in the peripheral blood of patients with lungcancer is plausible for early diagnosis and prognosis prediction of lung cancer.

Keywords： lung cancer     HSP90β     decision tree model     prognosis    

HTML PDF Collect

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies

Keywords： anlotinib     chemotherapy     short-term relapsed     small-cell lung cancer    

HTML PDF Collect

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 157-171 doi: 10.1007/s11684-013-0272-4

Abstract:

Non-small-cell lung cancer (NSCLC) is the most common cause of premature death among the malignant

Keywords： non-small-cell lung cancer     molecular typing     individualized medicine     molecular-targeted therapy     gene expression    

HTML PDF Collect

MicroRNAs and lung cancers: from pathogenesis to clinical implications

Ji Qi, David Mu

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 134-155 doi: 10.1007/s11684-012-0188-4

Abstract:

Lung cancer is the leading cause of cancer-related deaths in the US and worldwide.functions of small-RNA-based, posttranscriptional gene regulators, i.e. microRNAs, in the pathogenesis of lungmicroRNAs as markers for diagnosis, prognosis and the promising field of microRNA-based novel therapies for lung

Keywords： lung biology     lung cancer     microRNA    

HTML PDF Collect

combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lungcancer: a retrospective analysis

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 610-617 doi: 10.1007/s11684-021-0827-8

Abstract: Bevacizumab, an anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patients with advanced non-squamous NSCLC (ns-NSCLC). However, the safety and efficacy of bevacizumab for elderly patients with advanced NSCLC require further investigation. Thus, 59 patients were included in the present retrospective study, 22 patients in the bevacizumab plus pemetrexed and platinum (B+PP) group, and 37 patients in the pemetrexed and platinum (PP) group. For the entire cohort of patients, the median OS was 33.3 months, and the 1-year and 2-year overall survival rates were 88.5% and 67.8%, respectively. The median OS and 1-year and 2-year OS rates were 20.5 months, 70.3% and 0%, respectively, in the B+PP group and 33.4 months, 97.0% and 89.4%, respectively, in the PP group (P <0.001). The incidence of grade≥3 adverse events was higher in the B+PP group than in the PP group (27.3% vs. 10.8%, respectively; P=0.204). Univariate and multivariate analyses suggested that the receipt of≥5 cycles of first-line chemotherapy was an independent favorable prognostic factor for OS, whereas the addition of bevacizumab was an unfavorable prognostic factor. With increased toxicities, the addition of bevacizumab to PP does not improve the overall survival of elderly patients with advanced ns-NSCLC.

Keywords： bevacizumab     elderly patient     advanced non-small-cell lung cancer     overall survival     toxicity    

HTML PDF Collect

Functional XPF polymorphisms associated with lung cancer susceptibility in a Chinese population

Dian-Ke YU PhD, Chen WU MD, Wen TAN MD, Dong-Xin LIN MD,

Frontiers of Medicine 2010, Volume 4, Issue 1,   Pages 82-89 doi: 10.1007/s11684-010-0014-9

Abstract: cancer risk.function of promoter polymorphisms was tested by a set of biochemical assays, and their effects on lungcancer risk were determined by a case-control analysis of 988 patients with lung cancer and 986 controlsThe −673TT genotype was associated with a decreased risk of lung cancer compared with the CC genotypecancer.

Keywords： XPF     polymorphism     lung cancer    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract:

Lung cancer is the most common incident cancer and the leading cause of cancer death.cancer with a mutation rate of 10%.Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy.EGFRvIII-CART showed significantly efficient antitumor activity against lung cancer cells expressingcancer after surgery.

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Title Author Date Type Operation

The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China

Yize Xiao, Ying Shao, Xianjun Yu, Guangbiao Zhou

Journal Article

FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression

Journal Article

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Journal Article

Pathogenesis sequences in Gejiu miners with lung cancer: an introduction

Li Bian,Yonghua Ruan,Liju Ma,Hairong Hua,Li Zhou,Xiaoyu Tuo,Zheyan Zhou,Ting Li,Shiyue Liu,Kewei Jin

Journal Article

Curbing the burden of lung cancer

Alexandra Urman,H. Dean Hosgood

Journal Article

Orlistat induces ferroptosis-like cell death of lung cancer cells

Journal Article

Low-dose CT for lung cancer screening: opportunities and challenges

Hongbing Shen

Journal Article

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

Four-protein model for predicting prognostic risk of lung cancer

Journal Article

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Journal Article

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Journal Article

MicroRNAs and lung cancers: from pathogenesis to clinical implications

Ji Qi, David Mu

Journal Article

combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lungcancer: a retrospective analysis

Journal Article

Functional XPF polymorphisms associated with lung cancer susceptibility in a Chinese population

Dian-Ke YU PhD, Chen WU MD, Wen TAN MD, Dong-Xin LIN MD,

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article